Please Wait...

VEGF-A // Vascular Endothelial Growth Factor

Biomarker Therapeutic Areas: 
Biomarker Matrices: 

Vascular Endothelial Growth Factor A (VEGF-A or VEGF) is a member of the Platelet-derived growth factor (PDGF) family and is implicated in embryogenic development, angiogenesis and vascular permeability (Coultas et al., 2005). Biological activities of VEGF-A are mediated through binding with VEGFR-1 and VEGFR-2, two related tyrosine kinases receptors (Ferrara et al., 2003). VEGF-A exist under several isoforms (at least 7 different spliced variants) which have different capacities to bind heparin and heparin-sulfate and are differentially expressed during development (Byrne et al., 2005). Biological functions of VEGF-A are not limited to angiogenesis and vascular permeability, VEGF-A signaling has also an implication in the initiation of tumorigenesis and regulation of cancer cells microenvironment (Goel and Mercurio, 2013). High levels of VEGF-A in serum have also been found in several autoimmune diseases (Carvalho et al., 2007).

Bioclinica Lab employs a manual sandwich immunoassay for VEGF-A measurement in plasma.

ADDITIONAL RESOURCES

Biomarker Menu

Download MENU

Molecular Marker Laboratory Services

Download Brochure

Alzheimer's Disease Biomarker Lab Expertise

Download Info Sheet

Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

Bioclinica Delivers Individual Case Safety Report (ICSR) Processing w Quality & Consistency While Crossing One Mil… https://t.co/77NOME2Dj7
bioclinica (21 hours ago)
Who made the BioSpace list of 11 most innovative life sciences companies in the world? Ck it out here via @biospace… https://t.co/f9vtRpsbMW
bioclinica (Yesterday)
BREAKING: With a passion for Drug Safety, we’re delighted to share @bioclinica #pharmacovigilance crossed 1M ICSR c… https://t.co/PAdROjo7tE
bioclinica (Yesterday)
RT @isciencebox: Draft and Final FDA Guidances Detail Development of New Drugs for Neurological Disorders @RAPSorg https://t.co/cAewLypUY7
bioclinica (2 days ago)
RT @RAPSorg: Final @US_FDA Rule Requires Medical Device Trials Outside US to Conform to GCP | #Regulatory Focus https://t.co/jgwaqxfiXl #FD…
bioclinica (2 days ago)
Congrats @bioclinica on @Clin_Info_News Best Practices Award 4 "Transformational Med. Imaging in #ClinicalTrials. '… https://t.co/NxauNywq23
bioclinica (6 days ago)

Latest Blogs:

Latin America: Benefit from the Right Partner
Removing Risk from Clinical Trial Management System (CTMS) Implementations
Collaboration Between Clinical Operations and the Logistics and Supply Chain Teams is Key to Trial Success
The Value of Protocol Review
CTMS and RBM: Hot Topics at OCT Nordics in Copenhagen